LRBA expression is induced by mitogens in lymphoid and myeloid cells. The Drosophila LRBA orthologue rugose/ DAKAP550 is involved in Notch, Ras and EGFR pathways. These findings suggest that LRBA could play a role in cell types that have increased proliferative and survival capacity. Here, we show by microarray and realtime PCR analyses that LRBA is overexpressed in several different cancers relative to their normal tissue controls. We also show that LRBA promoter activity and endogenous LRBA mRNA levels are reduced by p53 and increased by E2F1, indicating that mutations in the tumor suppressors p53 and Rb could contribute to the deregulation of LRBA. Furthermore, inhibition of LRBA expression by RNA interference, or inhibition of its function by a dominant-negative mutant, leads to significant growth inhibition of cancer cells, demonstrating that deregulated expression of LRBA contributes to the altered growth properties of a cancer cell. Finally, we show that the phosphorylation of EGFR is affected by the dominantnegative mutant, suggesting LRBA plays a role in the mammalian EGFR pathway. These findings demonstrate that LRBA facilitates cancer cell growth and thus LRBA may represent a novel molecular target for cancer therapy.
LRBA expression is induced by mitogens in lymphoid and myeloid cells. The Drosophila LRBA orthologue rugose/ DAKAP550 is involved in Notch, Ras and EGFR pathways. These findings suggest that LRBA could play a role in cell types that have increased proliferative and survival capacity. Here, we show by microarray and realtime PCR analyses that LRBA is overexpressed in several different cancers relative to their normal tissue controls. We also show that LRBA promoter activity and endogenous LRBA mRNA levels are reduced by p53 and increased by E2F1, indicating that mutations in the tumor suppressors p53 and Rb could contribute to the deregulation of LRBA. Furthermore, inhibition of LRBA expression by RNA interference, or inhibition of its function by a dominant-negative mutant, leads to significant growth inhibition of cancer cells, demonstrating that deregulated expression of LRBA contributes to the altered growth properties of a cancer cell. Finally, we show that the phosphorylation of EGFR is affected by the dominantnegative mutant, suggesting LRBA plays a role in the mammalian EGFR pathway. These findings demonstrate that LRBA facilitates cancer cell growth and thus LRBA may represent a novel molecular target for cancer therapy.
Introduction
Characterization of genes responsive to lipopolysaccharide (LPS) led to the identification of a novel gene designated LPS-responsive and beige-like anchor (LRBA) (Kerr et al., 1996; Wang et al., 2001) . LRBA belongs to a novel gene family, the WBW gene family.
The genes of this family share a highly conserved WBW (WDL (WD-like)-BEACH-WD40) multidomain structure at their C-termini (Wang et al., 2001) . The WDL domain contains a potential pleckstrin homology (PH) super-fold (Wang et al., 2001; Jogl et al., 2002) . PH domains are known to bind inositol phospholipids and proteins (Blomberg et al., 1999) . The BEACH domain is highly conserved (Nagle et al., 1996) . The WD (TrpAsp)-40 repeats may mediate protein-protein interactions (Li and Roberts, 2001) . The functions of the WDL and the BEACH domains or the WBW structure are unknown. LRBA, like its orthologue AKAP550 (protein A kinase anchor protein) and its isoform neurobeachin, might contain protein kinase A (PKA) binding sites (Han et al., 1997; Wang et al., 2000 Wang et al., , 2001 Dyomin et al., 2002) . These structural features suggest that LRBA is likely to be a part of the signaling pathway that requires its interaction with other proteins, inositol phospholipids and/or PKA.
Structural analysis is important to elucidate LRBA function; however, meaningful clues are also provided by studies of its orthologues and paralogues. Mutations of the CHS1 (Chediak-Higashi Syndrome1) gene cause severe immunodeficiency and premature mortality in humans (Spritz, 1998) . Large volume sphere A (LvsA) and rg (rugose, AKAP550) are potential orthologues of LRBA in Dictyostelium and Drosophila, respectively (Han et al., 1997; Kwak et al., 1999) . LvsA is essential for cytokinesis (Kwak et al., 1999) . Genetic analysis indicates that rg interacts with multiple signaling pathways including EGFR, Notch and Ras pathways (Shamloula et al., 2002) . FAN (factor associated with neutral sphingomyelinase) is involved in tumor necrosis factor (TNF)-mediated apoptosis (Segui et al., 2001) . As LRBA has strong structural similarities with these genes, LRBA may have functions similar to those described above. However, the function of LRBA remains undetermined, nor has its importance in cancers been explored.
As LRBA is upregulated by a mitogen that promotes growth and survival of immune cells, its expression might also be increased in cancer cells where signaling pathways that drive growth or survival are constitutively active. Analysis of LRBA expression in tumors and normal tissues indicates LRBA is significantly upregulated in multiple tumor types. Furthermore, we found that E2F1 induces LRBA transcription, while p53 has the opposite effect. As P53 and E2F1 are important cell growth regulators, and are often mutated (p53) or dysregulated (E2F1, through retinoblastoma (RB) mutation) in cancers (Vogelstein et al., 2000; Sherr and McCormick, 2002) , LRBA might play a role in cancer cell growth or survival. Indeed, we show that the repression of LRBA expression by RNA interference (RNAi) and inhibition of its function by a dominantnegative mutant retards the growth of human cancer cells. Repression of LRBA expression by RNAi also sensitizes cancer cells to chemotherapeutic agents. Furthermore, the EGFR pathway is affected by expression of a dominant-negative mutant of LRBA, indicating that LRBA possibly influences EGFR signaling. In aggregate, our findings demonstrate that LRBA facilitates the growth and survival of cancers and may contribute to therapeutic resistance.
Results

Expression of LRBA is increased in multiple cancers and correlated to that of the estrogen receptor in breast cancer
Microarray indicates that LRBA is overexpressed in renal, pancreas, colorectal, lung ( Figure 1a ) and CNS cancers ( Figure 1b ) when compared to their normal tissue counterparts. LRBA is also significantly increased in adenocarcinoma, carcinoid and small-cell lung cancers in a lung cancer microarray database (Bhattacharjee et al., 2001) (Figure 1c ). Microarray analysis of six benign breast samples and 27 human primary breast tumor samples shows that the average LRBA signal is significantly higher in tumors than benign controls and higher in estrogen receptor (ER) positive breast tumors than ER-negative tumors (Table 1) . Microarray analyses also show that the murine orthologue Lrba, in the mammary gland, rises 1.7-2-fold over the course of pregnancy (data not shown). Since estrogen levels are elevated during pregnancy, this result further supports the idea that LRBA expression is correlated to ER status in breast cancer.
To confirm the microarray results, we conducted realtime RT-PCR measurements of LRBA levels in matched normal and tumor biopsies, as well as in MCF-7 breast adenocarcinoma and MCF-10A immortalized breast epithelium cells. This analysis shows that LRBA levels are increased several fold in prostate ( Figure 2a ) and breast tumors (Figure 2b) , and approximately two-fold in MCF-7 cells compared to MCF-10A cells (Figure 2b ).
The LRBA promoter is regulated by p53 and E2F transcription factors
To determine whether the LRBA promoter is responsible for the upregulation of LRBA in cancer cells, we cloned a 2 kB putative promoter region (GenBank AY141853) and identified four transcription start sites (Figure 3a ). Promoter activity analyses using a luciferase reporter system in H1299 lung adenocarcinoma cells (p53
indicate that p53 represses the activity of the LRBA promoter approximately 10-fold (Figure 3b ). Consistent with this, FACS analysis of GFP activity driven by LRBA promoter shows p53 had a 50% reduction in GFP positive cells (data not shown). Luciferase analysis of LRBA promoter activity in T98G glioblastoma cells shows that LRBA promoter activity is significantly increased approximately 11-fold by the exogenous wildtype E2F1 (Figure 3b ).
We also examined whether p53 and E2F1 affect the activity of the in situ LRBA promoter. Transfections were performed with the p53 or E2F1 expression vector and endogenous LRBA mRNA levels were measured by real-time RT-PCR. The results show that the mRNA levels of the endogenous LRBA were decreased by p53 in H1299 cells, but upregulated by E2F1 in T98G cells ( Figure 3c ). These results suggest that LRBA is regulated by p53 and E2F1.
Repression of LRBA by RNAi results in the death of human cancer cells
The determination that LRBA expression is increased in cancers, and that p53 and E2F1 have a significant impact on LRBA promoter activity, prompted us to pursue the question of whether increased LRBA expression is important to cell growth in cancer. RNAi experiments show that LRBA-specific siRNAs significantly reduce the growth of HeLa ( while siRNA controls had no impact on cell growth at the same concentration.
We also developed shRNA vectors to express interfering RNAs specific for LRBA and found that these vectors also very effectively inhibit the growth of various human cancer cells including HeLa (Figure 5a ), 293 and MCF-7 (Figure 5b ), MDA MB-361 breast cancer cells, A549 lung adenocarcinama and A431 epidermal carcinoma cells (data not shown). We also confirmed that these vectors significantly reduce LRBA mRNA levels, as determined by RT-PCR (Figure 5c ).
Inhibition of LRBA activity by a dominant-negative mutant also inhibits growth in human cancer cells
A truncated form of the FAN gene that encodes only the BEACH and WD40 domains is known to act as a dominant-negative mutant that blocks FAN function (Adam-Klages et al., 1996). We also found that the BW show that LRBA mRNA expression levels are significantly reduced by an LRBA-specific shRNA vector. HeLa cells were transfected with LRBA shRNA vector or the control shRNA vector, at 72 h after transfections; total RNA was extracted and RT-PCR was carried out using LRBA primers or b-actin-specific primers, as described in Materials and methods region of LRBA can serve as a dominant-negative mutant. Proliferation of MCF-7 breast adenocarcinoma cells is significantly inhibited by expression of the BW mutant (without doxycycline) at viral dilutions of 1 : 10, 1 : 50 and 1 : 100 (Figure 6a ). These results mirror our LRBA knockdown studies of MCF-7 cells (Figure 4c ) and thus provide an independent demonstration that LRBA expression and function are important for cancer cell growth and/or survival. The overexpression of the BW protein in the absence of doxycycline and nonexpression of the BW protein in the presence of doxycycline was confirmed by Western blot (Figure 6b ) and fluorescence microscopy ( Figure 6c ).
LRBA knockdown sensitizes cancer cells to apoptosis
The above results suggest that increased LRBA levels in a tumor cell might endow that cell with enhanced growth and survival capacity. Thus, reducing LRBA level may sensitize cancer cells to apoptosis. To examine this possibility, we transfected cells with LRBA-specific siRNAs, irrelevant siRNAs or H 2 O. The cells were then treated with UV or staurosporine to induce apoptosis. Results show that LRBA depletion enhances apoptosis, as determined by a viable cell count (Figure 7a ) and molecular analysis of PARP and caspase-3 cleavage (Figure 7b ). There is more cleaved PARP and caspase-3 in HeLa cells treated with LRBA siRNA, indicating that LRBA increases the threshold for the induction of apoptosis. We further tested this hypothesis by showing that a conventional chemotherapeutic, cisplatin, when combined with LRBA gene suppression, results in a greater reduction in tumor cell growth than observed in cancer cells treated with cisplatin or LRBA shRNA alone (Figure 7c ). These findings suggest that LRBA knockdown when combined with cancer therapeutics may achieve a greater tumor kill than either entity alone.
LRBA is involved in regulation of EGFR
Our RNAi or dominant-negative studies demonstrate that LRBA plays a role in cancer cell growth. However, the underlying molecular function of LRBA remains undetermined. We find, like its orthologue, rugose/AKAP550, that the mammalian LRBA also interacts with the EGFR pathway. The EGF stimulation experiments show that the dominant-negative mutant (without doxycycline) reduces the phosphorylation of EGFR and MAPK when compared to the controls (with doxycycline). The levels of phosphorylated EGFR estimated are reduced 3.6, 1.9 and 1.2 times in each treatment pair ( 
Discussion
Our microarray analyses show LRBA is overexpressed in several different cancers, and its expression levels vary greatly in different tissues and developmental stages, suggesting that LRBA may play a regulatory role rather than a structural one, and that its expression is tightly controlled. The LRBA promoter is very complex, having multiple transcription start sites, a CpG island and multiple putative binding sites for key cell cycle or apoptosis-related transcription factors, such as E2F, ER and p53. LRBA promoter activity and endogenous LRBA mRNA levels are reduced by p53 and increased by E2F1 and the expression of LRBA is correlated to that of ER in breast cancer. Thus, LRBA expression may be increased in cancers where p53 is mutated, and/ or E2F1 is constitutively active.
The findings that LRBA is regulated by p53, E2F1 and possibly by ER also suggest that LRBA may be involved in cell proliferation and apoptosis. P53 responds to genotoxic stress to maintain genomic integrity by cell arrest, or by inducing apoptosis (Bargonetti and Manfredi, 2002) . The E2F family of transcription factors plays a crucial role in G1/S transition (Ohtani, 1999) . The p53-mediated repression of the LRBA promoter may imply that LRBA plays some role in suppressing apoptosis, and therefore p53 must reduce its expression in order to facilitate apoptosis. In contrast, the E2F upregulation of the LRBA promoter may imply that LRBA also facilitates increased proliferation or survival of a cancer cell. Thus, inhibition of LRBA may repress cancer cell growth.
Two independent approaches to inhibit LRBA expression or function, siRNA-mediated mRNA knockdown and an LRBA dominant-negative mutant, both inhibit growth of tumor cells, demonstrating that deregulated expression of LRBA contributes to the altered growth properties of a cancer cell. Although the molecular mechanism underlying LRBA regulation of cell growth remains undefined, we have found that the EGFR pathway is affected by a dominant-negative mutant of LRBA, indicating LRBA involvement in EGFR signaling. This result agrees with previous findings that the LRBA ortholog rg/AKAP550 is genetically involved in EGFR signaling (Shamloula et al., 2002) .
The regulation of EGFR consists of receptor dimerization, phosphorylation, internalization, recycling and degradation upon EGF stimulation (Jorissen et al., 2003; Wiley, 2003) . Electron microscopy of Lrba subcellular localization indicated its presence at multiple sites, including the plasma membrane, clathrin-coated pits and lysosomes (Wang et al., 2001 ). These subcellular localizations are required for EGFR regulation (Jorissen et al., Wiley, 2003) . Presently, we find that a dominantnegative mutant of LRBA affects EGFR phosphorylation. We thus hypothesize that LRBA, functioning as a vesicle trafficking regulator, is required for EGFR activation (Figure 9 ). However, it is unlikely that EGFR is the only pathway affected by LRBA. LRBA is a very complicated multiple domain protein; like its othologue, rg/AKAP550, it may interact with multiple proteins and multiple pathways, such as the PKA pathway. EGFR family receptors (EGFR, Her2) and PKA are overexpressed in most cancers, and are associated with high proliferation and resistance to hormono-, chemo-and radio-therapy (Miller, 2002; Morris, 2002) . Since LRBA is involved in the EGFR and potentially PKA pathways (Shamloula et al., 2002) , inhibition of LRBA may impair these pathways, leading to the growth inhibition and therapeutic sensitization of cancer cells.
We thus hypothesize that LRBA functions as a positive regulator of cell survival by facilitating cell proliferation and antiapoptosis, the two hallmarks of cancer. Therefore, when overexpressed in cancers, LRBA would endow a cancer cell with increased proliferation and/or increased resistance to apoptosis, and thus increase resistance to therapies based on apoptosis induction. In contrast, repression of LRBA expression or function would inhibit caner cell growth and sensitize cancer cells to therapy, when combined with traditional therapeutics might efficiently kill cancer cells. Thus, LRBA may represent a novel molecular target for cancer therapy. 
Materials and methods
Reagents
Cell culture
Cell lines were purchased from the American Type Culture Collection (Manassas, VA, USA) and maintained according to the company's instructions. Otherwise specified elsewhere.
Microarray analysis
In all experiment 5 mg of total RNA served as the mRNA source for microarray analysis. The poly(A) RNA was specifically converted to cDNA and then amplified and labeled with biotin following the previous procedure (Van Gelder et al., 1990) . Hybridization with the biotin-labeled RNA, staining and scanning of the chips followed the Affymetrix technical manual, and has been previously described (Warrington et al., 2000) . The oligonucleotide probe arrays are Affymetrix U95A and HU6800 chips (Affymetrix, Santa Clara, CA, USA). Scanned output files were visually inspected for hybridization artifacts and then analysed by using Affymetrix Microarray 4.0 software. Some microarray data were kindly provided by R Jove and G Bepler at H Lee Moffitt Cancer Center (Bloom et al., 2004) .
RT-PCR and real-time PCR
Total RNA was extracted from 5 Â 10 5 cells and purified via the RNAqueous 4-PCR kit (Ambion, Austin, TX, USA) following the manufacturer's protocol, then transcribed to cDNA using oligo-dT primers (Invitrogen) and Superscipt II Reverse transcriptase (Invitrogen), following the manufacturer's protocol. The synthesized cDNA mixture was then diluted at 1 : 10 and used (2-4 ml) for either PCR with the primers -for LRBA: 5 0 TCACCCCAAAAGGATTAGAT GGACC3 0 and 5 0 GAAAGAAAGGCTCTGCGAACCTCC3 0 ; for b-actin: 5 0 TGACGGGGTCACCCACACTGTGCC3 0 and 5 0 TAGAAGCATTTGCGGTGGACGATG3 0 , or by real-time PCR with the primers -for LRBA: 5 0 CCAACTTCAGAGAT TTGTCCAAGC3 0 and 5 0 ATGCTGCTCTTTTTGGGTTC AG3 0 ; for b-actin: 5 0 ATTGCCGACAGGATGCAGAA3 0 and 5 0 GCTGATCCACATCTGCTGGAA3 0 . ABI PerkinElmer Prism 7700 Sequence Detection System (Applied Biosystems, Inc., Foster City, CA, USA) and SYBR Green Quantitect Master Mix (Qiagen, Valencia, CA, USA) were used for real-time PCR following the manufacturer's protocol.
RACE and determination of the transcription start sites
Switching mechanism at 5 0 end of RNA transcript (SMART) rapid amplification of cDNA ends (RACE) amplification kit (Clontech, Palo Alto, CA, USA) was used to map the 5 0 end of LRBA gene transcripts. The 5 0 cDNA of LRBA gene was synthesized from 2.5 mg of normal prostate or prostate tumor total RNA by reverse transcription using the PowerScript Reverse Transcriptase (Clontech) and LRBA-specific primer 5 0 CACACAGAGCATTGTAGCAAGCTCCTC3 0 . The first Figure 9 Model for interaction of LRBA with the EGF receptor family signaling pathways. We hypothesize that LRBA is involved in the activation of EGFR pathway. Our model predicts that E2F upregulates LRBA, p53 downregulates LRBA, LRBA enhances EGFR signaling, which leads to the activation of E2F1. The activation of the E2F1 may upregulate LRBA that positively feedback on EGFR signaling PCR reaction was carried out using the LRBA specific primer 5 0 GGGCACTGGGGAGAATTTCGAAGTAGG3 0 and UPM primer from the kit, following the manufacturer's recommendation. Primers for the secondary PCR amplification are 5 0 TGCAGACTTGAAGATTCCG3 0 and NUP primer from the kit. The Advantage polymerase mix (Clontech) was used for these PCR amplifications. The PCR products were cloned and sequenced.
Cloning and sequencing of the LRBA promoter Based on the genomic sequence in GenBank (AC011122) and our sequences from 5 0 RACE, we designed PCR primers to amplify a 2 kb putative promoter fragment from human genomic DNA extracted from MCF-10A cells by DNeasy tissue kit (Qiagen). The primers are: 5'cgcctcgagCGGCTTCT GTCCACTTCTCAAGGC3 0 and 5 0 cccaagcttATCTCTCTC CCCGAGGCTGACAAC3 0 . The amplification was carried out by using Advantage-GC Genomic PCR Kit (Clontech) and 5 ml GC-Met for 50 ml PCR reaction, following the manufacturer's recommendation. This 2 kb PCR product was cloned into the pGL2 vector (Promega, Madison, WI, USA) to obtain the pLA-luc luciferase reporter vector. Sequencing of the LRBA promoter was performed by the following primers:
0 . LRBA sequences are in upper case.
Luciferase assays for LRBA promoter analysis
Cells were seeded 24 h prior to transfection in a 24-well plate at a density of 1 Â 10 5 cells per well. The pLA-luc vector was cotransfected with p53 or E2F1 gene expression vectors into H1299 or T98G cells using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol. For p53 assays, the vectors pCMV-p53 or pCMV-p53 mt135 (Clontech) were used. For E2F assays, pcDNA E2F1wt, pE2F2wt, pE2F3a and pcDNAE2F1eco132 were used. In all experimental systems, a Renillan luciferase control vector, pRL-TK, pRL-CMV, or pRL-Null (Promega) was cotransfected with the pLA-luc. Luciferase assays were performed using the Dual Luciferase Reporter Assay System (Promega) following the manufacturer's protocol. Luciferase activity was detected using a Lumat LB9501 luminometer (Berthold Technologies, Oak Ridge, TN, USA). The luciferase activity units were normalized to the Renillan luciferase control.
SiRNA knockdown
LRBA siRNA oligonucleotides were synthesized and purified by Dharmacon (Lafayette, CO, USA). At 1 day before transfection, HeLa cells were seeded in a 24-well plate at 2 Â 10 4 cells per well. The LRBA siRNA (siRNA1: 5 0 AACCAGCAAAGGUCUUGGCUA3 0 , siRNA2: 5 0 AAG GGCACUCUUUCUGUCACCUU3 0 ) and control siRNA (luciferase: 5 0 AACGUACGCGGAAUACUUCGA3 0 , scramble siRNA: 5 0 CAGUCGCGUUUGCGACUGG3 0 ) duplexes at 50 nM were transfected into HeLa cells following the previous protocol (Harborth et al., 2001) . At 48-72 h posttransfection, cells were trypsinized to obtain a single-cell suspension and counted with a Coulter counter (Beckman coulter, Inc., Fullerton, CA, USA) or via Trypan blue exclusion assay. Knockdown of LRBA mRNA levels was confirmed by RT-PCR using primers 5 0 GGTGGACCTAC TGGAAAAATGTGAC3 0 and 5 0 TAGCCAAGACCTTTGC TGGTTC 3 0 .
Construction of recombinant adenovirus
The replication-deficient recombinant adenovirus designated AdBWGFP, which expresses GFP-tagged BW (BEACH-WD) region of mouse Lrba, was generated by Adeno-X Tet-Off Expression Systems (Clontech) following the manufacturer's instructions. Briefly, the recombinant adenoviral plasmid was linearized and transfected into 293 cells (Clontech) using FuGENE 6 (Roche Molecular Biochemicals), as recommended by the supplier. After 4-7 days, cell suspension was cleared by centrifugation (1500 g) for 5 min, and the supernatant containing B10 3 viral particles were frozen at À801C. High titer viral stocks were prepared following the previous protocol (He et al., 1998) .
Cell proliferation assays
MCF-7 Tet-Off cells (Clontech) were seeded in a 96-well plate at 2 Â 10 4 cells per well and cultured for 24 h. Cells were infected with different titer of the recombinant AdBWGFP adenoviruses. Doxycycline (Clontech), which represses expression of the BWGFP fusion protein, was used at 1 mg/ml. After 72 h post infection, cells were labeled with 3 H thymidine (1 mCi per well). After 18 h, cells were harvested by EDTA-trypsin and CPM measured.
Construction of shRNA plasmids
The following oligos and their complement oligos were synthesized and PAGE purified by Invitrogen, then annealed and cloned into the pBS/U6 vector separately, following the methods described previously (Sui et al., 2002) 
Colony-forming assays
HeLa cells were plated in a 24-well plate at 5 Â 10 5 /well 1 day before transfection. Transfections were conducted using Lipofectamine 2000 (Invitrogen) following the manufacturer's protocol with some modifications. Less (0.2 ml per well) Lipofectamine 2000 and more OPTI media (200 ml per well) were used to reduce the toxicity. After 12 h, 300 ml of DMEM complete medium was added to each well. After another 12 h, HeLa cells in each well were trypsinized, transferred to one 100 mm plate, and incubated for 10-14 days with G418 at 400 mg/ml. Colonies were stained with 0.5 ml of 0.005% Crystal Violet for 30 min to enable enumeration of colonies.
Western immunoblotting analysis
For preparation of cellular protein, cells were rinsed with PBS and lysed in RIPA containing 100 mg/ml phenyl-methylsulfonyl fluoride, 2 mg/ml aprotinin, 2 mg/ml leupeptin and 1% NP-40 (lysis buffer). Protein concentrations of cell lysates were determined by Coomassie Plust Protein Assay Kit (Pierce). Cellular protein (100 mg) was loaded onto an 8-12% SDS-PAGE gel (Invitrogen) and transferred to PVDF or nitrocellular membranes. Membranes were blocked for 1 h at room temperature in 5% milk, washed with PBST (PBS with 0.1% Tween-20) and incubated with the indicated antibodies for 1 or 24 h. Membranes were washed three times in PBST and HRPconjugated secondary antibody was added at 1 : 2000 to 80 000 in 5% milk for 1 h. Membranes were washed and detected by ECL (Amersham Life Science, Piscataway, NJ, USA) or the SuperSignal West Femto Kit (Pierce, Rockford, IL, USA) and exposed to an X-ray film (Kodak, Rochester, NY, USA). In some cases, blots were stripped with Restoret Western Blot Stripping Buffer (Pierce) and reprobed with other primary antibodies.
EGF stimulation assay
HeLa cells were seeded at 1 Â 10 5 /well (24-well plate). After 24 h, the media were removed and replaced with 200 ml OPTI media containing the AdBWGFP recombinant adenovirus with or without doxycycline. After 24 h, the media were removed and replaced with 200 ml OPTI media containing different concentrations of EGF. The cells were incubated at 371C for different times, then lysed with RIPA buffer and Western blot analysis was performed as described above.
Statistical analysis
Prism v3.0. was used to make all column bar graphics and calculate the statistical significance of the experimental results by using a two tailed unpaired T-test at 95% confidence intervals. Po0.05 was considered to be statistically significant and is marked with * in the figures.
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